EXPEDITED PUBLICATION
Discriminating Between Cardiac and Pulmonary Dysfunction in the General Population With Dyspnea by Plasma Pro-B-Type Natriuretic Peptide
Rasmus Mogelvang, MD*, ,*,
Jens P. Goetze, MD, DMSc*, ,
Peter Schnohr, MD, DMSc*,
Peter Lange, MD, DMSc*, ,
Peter Sogaard, MD, DMSc,
Jens F. Rehfeld, MD, DMSc and
Jan S. Jensen, MD, PhD, DMSc*,
* Copenhagen City Heart Study, Epidemiological Research Unit, Bispebjerg Hospital, University of Copenhagen, Copenhagen, Denmark
Department of Cardiology, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark
Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Heart and Lung Diseases, Hvidovre Hospital, University of Copenhagen, Copenhagen, Denmark.
Manuscript received May 14, 2007;
revised manuscript received July 5, 2007,
accepted July 23, 2007.
* Reprint requests and correspondence: Dr. Rasmus Mogelvang, Department of Cardiology, Gentofte Hospital, University of Copenhagen, Post 4210, 65 Niels Andersens Vej, DK-2900 Hellerup, Denmark. (Email: Rasmus.Mogelvang{at}get2net.dk).
Objectives: This study was designed to determine whether measurement of plasma pro-B-type natriuretic peptide (proBNP) could be used in discriminating between cardiac and pulmonary dyspnea in the general population.
Background: Natriuretic peptides are useful markers in ruling out acute cardiac dyspnea in the emergency department, but their diagnostic significance in evaluating chronic dyspnea in the general population is unknown.
Methods: Within the Copenhagen City Heart Study, a large, community-based population study, dyspnea was evaluated by spirometry, oxygen saturation, echocardiography, and plasma proBNP.
Results: Of 2,929 participants, 959 reported dyspnea. The plasma proBNP concentration was higher in the group with dyspnea (mean 17.8 pmol/l; 95% confidence interval [CI] 16.3 to 19.4 pmol/l) than in the group without (10.6 pmol/l; 95% CI 10.0 to 11.4 pmol/l; p < 0.001). In the group with dyspnea, left ventricular hypertrophy and/or systolic dysfunction was associated with a 2.6-fold increase in plasma proBNP concentration (p < 0.001), whereas pulmonary dysfunction was not associated with increased plasma proBNP (p = 0.66). Using multivariable regression analysis, a model to estimate the expected concentration of plasma proBNP based on age and gender was established for dyspneic subjects: an actual plasma proBNP concentration below half of the expected value ruled out left ventricular systolic and diastolic dysfunction (sensitivity 100%, 95% CI 100% to 100%; specificity 15%, 95% CI 12% to 17%).
Conclusions: In the general population with dyspnea, plasma proBNP concentrations are increased in left ventricular dilatation, hypertrophy, systolic dysfunction, or diastolic dysfunction, but are unaffected by pulmonary dysfunction.
|
Abbreviations and Acronyms
| | CI = confidence interval | | FEV1
= forced expiratory volume in 1 s | | FVC = forced vital capacity | | MRC = Medical Research Council | | NPV = negative predictive value | | PPV = positive predictive value | | ProBNP = pro-B-type natriuretic peptide | | ROC = receiver-operator characteristic |
|
Related Article
-
B-Type Natriuretic Peptides and the General Practitioner
- Christian Mueller
J. Am. Coll. Cardiol. 2007 50: 1702-1703.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Christensen, R. Mogelvang, M. Heitmann, and E. Prescott
Level of education and risk of heart failure: a prospective cohort study with echocardiography evaluation
Eur. Heart J.,
February 2, 2011;
32(4):
450 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Arenja, T. Socrates, and C. Mueller
Chapter 7 Acute dyspnoea
The ESC Textbook of Acute and Intensive Cardiac Care,
December 1, 2010;
1(1):
med-9780199584314-chapter - med-9780199584314-chapter.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mogelvang, P. Sogaard, S. A. Pedersen, N. T. Olsen, J. L. Marott, P. Schnohr, J. P. Goetze, and J. S. Jensen
Cardiac Dysfunction Assessed by Echocardiographic Tissue Doppler Imaging Is an Independent Predictor of Mortality in the General Population
Circulation,
May 26, 2009;
119(20):
2679 - 2685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mogelvang, P. Sogaard, S. A. Pedersen, N. T. Olsen, P. Schnohr, and J. S. Jensen
Tissue Doppler echocardiography in persons with hypertension, diabetes, or ischaemic heart disease: the Copenhagen City Heart Study
Eur. Heart J.,
March 2, 2009;
30(6):
731 - 739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. Goetze, U. Dahlstrom, J. F. Rehfeld, and U. Alehagen
Impact of Epitope Specificity and Precursor Maturation in Pro-B-Type Natriuretic Peptide Measurement
Clin. Chem.,
November 1, 2008;
54(11):
1780 - 1787.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. J. MacFadyen and M. J. Ng Kam Chuen
Biomarker Sensitivity and Specificity Require Pre-Test Probability of Disease Diagnosis to Be Collated: Additional Points on the Interpretation of Pro-B-Type Natriuretic Peptide Triage of Dyspnea in the Copenhagen Heart Study
J. Am. Coll. Cardiol.,
April 1, 2008;
51(13):
1322 - 1323.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Mogelvang, J. P. Goetze, P. Schnohr, P. Lange, P. Sogaard, J. F. Rehfeld, and J. S. Jensen
Reply
J. Am. Coll. Cardiol.,
April 1, 2008;
51(13):
1323 - 1323.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Bozinovski, A. Hutchinson, M. Thompson, L. MacGregor, J. Black, E. Giannakis, A.-S. Karlsson, R. Silvestrini, D. Smallwood, R. Vlahos, et al.
Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
February 1, 2008;
177(3):
269 - 278.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mueller
B-Type Natriuretic Peptides and the General Practitioner
J. Am. Coll. Cardiol.,
October 23, 2007;
50(17):
1702 - 1703.
[Full Text]
[PDF]
|
|
|
|
